The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality
Open accessAbstract
Objectives: The epidemiology and clinical course of candidaemia in patients with acute leukaemia, a population frequently exposed to antifungals, have not been extensively studied. In the present contemporary series of acute leukaemia patients, we describe patient characteristics, Candida species and MIC distributions and investigate the association between antifungal resistance and all-cause mortality. Methods: We performed a retrospective review of medical records and microbiological data of adult patients with acute leukaemia or high-risk myelodysplastic syndrome with at least one positive blood culture for Candida species at the MD Anderson Cancer Center between January 2008 and October 2012. Susceptibility was defined according to the 2012 epidemiological cut-off values and clinical breakpoints. Results: We identified 67 episodes of candidaemia in 65 patients. Almost all episodes (94%) occurred in patients who were receiving antifungal agents, 71% in patients receiving an echinocandin. Almost all isolates (99%) were of non-albicans Candida species [most frequently Candida parapsilosis (32%), Candida tropicalis (23%) and Candida glabrata (20%)]. Caspofungin non-susceptibility was significantly associated with fluconazole resistance (P < 0.001). Non-susceptibility to caspofungin and multidrug resistance were associated with excess 14 day [adjusted HR (aHR) 3.02 (95% CI 1.28–7.09), P = 0.011 and aHR 3.02 (95% CI 1.27–7.14), P = 0.012, respectively] and 30 day [aHR 2.96 (95% CI 1.38–6.37), P = 0.005 and aHR 2.86 (95% CI 1.31–6.21), P = 0.008, respectively] all-cause mortality. Conclusions: In patients with acute leukaemia, a shift in candidaemia epidemiology was noted with a 99% predominance of non-albicans species. Non-susceptibility of Candida strains to caspofungin or multidrug resistance were independent markers of poor outcome in this patient population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
11.1%-58.3% of C. glabrata isolates resistant to echinocandins had cross resistance against fluconazole or other azoles.
“As a result, 11.1%–58.3% of C. glabrata isolates resistant to echinocandins had cross resistance against fluconazole or other azoles [168,169,172]”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [168]
Signs of multidrug resistance amongst azoles and echinocandins have already been described.
“The use of echinocandins and development of cross-resistance is creating apprehension, for the signs of multidrug resistance amongst azoles and echinocandins have already been described [168,169,170].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J. A., Winston, D. J., Perfect, J. R., Ullmann, A. J., Walsh, T. J., HELFGOTT, D. C., Hołowiecki, J., Stockelberg, D., Goh, Y. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,802 · see citing works
(2006) · PubMed · Cited by 906 · see citing works
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · see citing works
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656 · see citing works
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 608 · see citing works
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · see citing works
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484 · see citing works
The changing epidemiology of invasive candidiasis
Hachem, R. Y., Hanna, H. A., Kontoyiannis, D. P., Jiang, Y., & RAAD, I. I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 330 · see citing works
Self-citationPredictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295 · see citing works
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269 · see citing works
Self-citationInfectious and immunosuppressive complications of purine analog therapy.
Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2431 · Cited by 263 · see citing works
Lewis, R. E., Cahyame‐Zuniga, L., Leventakos, K., Chamilos, G., Ben‐Ami, R., Tamboli, P., Tarrand, J. J., Bodey, G. P., Luna, M. A., & Kontoyiannis, D. P. (2013) · Mycoses · doi:10.1111/myc.12081 · Cited by 248 · see citing works
Self-citationNucci, M., Anaissie, E., Betts, R. F., Dupont, B. F., Wu, C., Buell, D. N., Kovanda, L., & Lortholary, O. (2010) · Clinical Infectious Diseases · doi:10.1086/653935 · Cited by 228 · see citing works
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 204 · see citing works
Bow, E. J., Loewen, R., Cheang, M., & Schacter, B. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.2.361 · Cited by 181 · see citing works
Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection
Ben‐Ami, R., Olshtain‐Pops, K., Krieger, M., Oren, I., Bishara, J., Dan, M., Weil‐Weiner, Y., Weinberger, M., Zimhony, O., Chowers, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05947-11 · Cited by 178 · see citing works
Self-citationAntifungal therapy with an emphasis on biofilms
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.008 · Cited by 173 · see citing works
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
Slavin, M. A., Sorrell, T. C., Marriott, D., Thursky, K., Nguyen, Q. A., Ellis, D. H., Morrissey, C. O., Chen, S. C.-A., & on behalf of the Australian Candidemia Study, A. S. F. I. D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq053 · Cited by 163 · see citing works
Ben-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S., & Kontoyiannis, D. P. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir351 · Cited by 162 · see citing works
Self-citationManagement of central venous catheters in patients with cancer and candidemia
Raad, I., Hanna, H., Boktour, M., Girgawy, E., Danawi, H., Mardani, M., Kontoyiannis, D., Darouiche, R., Hachem, R., & Bodey, G. P. (2004) · Clinical Infectious Diseases · doi:10.1086/382874 · Cited by 159 · see citing works
Self-citationRobak, T., Lech‐Marańda, E., Korycka, A., et al. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778742918 · Cited by 154 · see citing works
Drug-Resistant<i>Candida glabrata</i>Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152 · see citing works
Self-citationThe case for antifungal stewardship
Ananda-Rajah, M. R., Slavin, M. A., & Thursky, K. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834e0680 · Cited by 128 · see citing works
Garnacho‐Montero, J., Díaz‐Martín, A., García-Cabrera, E., de Pipaón, M. R. P., Hernandez-Caballero, C., & Lepe, J. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks347 · Cited by 113 · see citing works
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00136-13 · Cited by 105 · see citing works
Farmakiotis, D., Kyvernitakis, A., Tarrand, J. J., & Kontoyiannis, D. P. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.07.006 · Cited by 86 · see citing works
Self-citationEpidemiology of Candida kefyr in Patients with Hematologic Malignancies
Dufresne, S. F., Marr, K. A., Sydnor, E. R. M., Staab, J. F., Karp, J. E., Lu, K. Y., Zhang, S. X., Lavallée, C., Perl, T. M., & Neofytos, D. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-14 · Cited by 71 · see citing works
Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia
Kim, S., Yoon, Y. K., Kim, M. J., & Sohn, J. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt256 · Cited by 69 · see citing works
Liu, C. Y., Huang, L. J., Wang, W. S., Chen, T. L., Yen, C. C., Yang, M. H., Hsiao, L. T., Liu, C. Y., Chen, P. M., & Chiou, T. J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2008.12.008 · Cited by 67 · see citing works
Infectious complications of purine analog therapy
Samonis, G., & Kontoyiannis, D. P. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200108000-00002 · Cited by 57 · see citing works
Self-citationShields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01451-13 · Cited by 56 · see citing works
Ostrosky‐Zeichner, L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit140 · Cited by 51 · see citing works
Farmakiotis, D., & Kontoyiannis, D. P. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13186 · Cited by 39 · see citing works
Self-citationFungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33 · see citing works
Self-citationFarmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00051-14 · Cited by 8 · see citing works
Self-citationDoxorubicin selects for fluconazole-resistant petite mutants in Candida glabrata isolates
Schulz, B., Knobloch, M., Weber, K., & Ruhnke, M. (2012) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2012.04.002 · Cited by 4 · see citing works
Jung, D. S., Farmakiotis, D., Jiang, Y., et al. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu052.992 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hema- tologic malignancies in the era of new antifungal agents (2001 -2007). Cancer 2009; 115: 4745 -52.
- Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multi-drug resistant Candida. Clin Infect Dis 2013; 56: 1733-4.
- Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
- Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Application of the com- bined CLSI/EUCAST breakpoints for azole and echinocandin susceptibilities of Candida isolates in a tertiary cancer center: the emerging threat of multi-drug resistance. In: Abstracts of the Twelfth Annual American Society for Microbiology Conference on Candida and Candidiasis, New Orleans, LA, 2014. Abstract S8:5, p.
Cited by
Sorted by citations
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636 · see citing works
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900 · see citing works
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177 · see citing works
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129 · see citing works
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Rausch, C. R., DiPippo, A. J., Bose, P., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy406 · Cited by 107 · see citing works
Self-citationPfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84 · see citing works
Zhai, B., Liao, C., Jaggavarapu, S., Tang, Y., Rolling, T., Ning, Y., Sun, T., Bergin, S. A., Gjonbalaj, M., Miranda, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03183-4 · Cited by 62 · see citing works
Rate of<i>FKS</i>Mutations among Consecutive Candida Isolates Causing Bloodstream Infection
Shields, R. K., Nguyen, M. H., Press, E. G., Cumbie, R., Driscoll, E., Pasculle, A. W., & Clancy, C. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01973-15 · Cited by 55 · see citing works
Bassetti, M., Vena, A., Bouza, E., Peghin, M., Muñoz, P., Righi, E., Pea, F., Lackner, M., & Lass-Flörl, C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.02.017 · Cited by 40 · see citing works
- Authors
- Wang, E., Farmakiotis, D., Yang, D., McCue, D. A., Kantarjian, H. M., Kontoyiannis, D. P., & Mathisen, M. S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Farmakiotis, Dimitrios
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-07
- Volume
- 70
- Issue
- 8
- Pages
- 2362-2368
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC6366596
- OpenAlex
- W2171191979
- Cited by
- 82
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 2 · 2018: 6 · 2017: 17 · 2016: 13 · 2015: 5
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Cancer Institute (P30CA015704)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- candidemia, acute leukemia, multidrug resistance, all-cause mortality, non-albicans Candida, Candida parapsilosis, Candida tropicalis, Candida glabrata, echinocandins, fluconazole resistance, antifungal susceptibility, high-risk myelodysplastic syndrome
- MeSH terms
- Caspofungin, Adult, Aged, Candida, Female, Humans, Leukemia, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Survival Analysis, Drug Resistance, Multiple, Fungal, Echinocandins, Lipopeptides, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
